Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The dorsal column of the spinal cord is a major ascending white matter tract located in the posterior portion (back) of the spinal cord, composed mainly of the gracile fasciculus (medially, lower body) and the cuneate fasciculus (laterally, upper body)[3]. It forms the first part of the dorsal column–medial lemniscus pathway (DCML), a sensory pathway in the central nervous system that conveys fine touch, vibration, pressure, two-point discrimination, and conscious proprioception from the skin and joints to the brain. Signals travel through the dorsal root ganglia, enter the spinal cord, ascend the dorsal columns, synapse in the medulla, and ultimately reach the somatosensory cortex. Lesions of this tract result in characteristic sensory deficits but it is not a molecular drug target in itself[1][2][3]. Key point: The "spinal cord dorsal column" is an anatomical structure (a white matter tract), not a molecule, receptor, or protein, and thus does not fit the normal pattern for drug discovery molecular targets[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dorsal column of the spinal cord.